Ian C.  Read net worth and biography

Ian Read Biography and Net Worth

CEO of Pfizer
Mr. Read began his career at Pfizer in 1978 and was named CEO in 2010 and Chairman of the Pfizer Board of Directors in 2011. During Mr. Read’s tenure as CEO, Pfizer generated a total shareholder return of 250%, achieved 32 FDA approvals for new medicines, invested significantly in research and development, and completed several transformational transactions to help strengthen Pfizer’s pipeline. Previously, Mr. Read served as Senior Vice President and Group President of Pfizer’s Worldwide Biopharmaceutical Businesses, overseeing five global business units: Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Prior to this, he held positions in several of the company’s largest, fastest-growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. Mr. Read continues to serve on the board of directors of Kimberly-Clark and Viatris while also being Chairman of DXC.

Mr. Read earned his B.S. in chemical engineering from London University Imperial College and subsequently became a Charted Accountant of England and Wales.

What is Ian C. Read's net worth?

The estimated net worth of Ian C. Read is at least $31.79 million as of July 16th, 2018. Mr. Read owns 1,145,693 shares of Pfizer stock worth more than $31,792,981 as of March 28th. This net worth approximation does not reflect any other assets that Mr. Read may own. Learn More about Ian C. Read's net worth.

How do I contact Ian C. Read?

The corporate mailing address for Mr. Read and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Ian C. Read's contact information.

Has Ian C. Read been buying or selling shares of Pfizer?

Ian C. Read has not been actively trading shares of Pfizer during the last quarter. Most recently, Ian C. Read sold 486,753 shares of the business's stock in a transaction on Monday, July 16th. The shares were sold at an average price of $37.36, for a transaction totalling $18,185,092.08. Following the completion of the sale, the chief executive officer now directly owns 1,145,693 shares of the company's stock, valued at $42,803,090.48. Learn More on Ian C. Read's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, Pfizer insiders bought shares 3 times. They purchased a total of 5,000 shares worth more than $156,410.00. The most recent insider tranaction occured on December, 15th when Director Scott Gottlieb bought 3,000 shares worth more than $79,410.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 12/15/2023.

Ian C. Read Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/16/2018Sell486,753$37.36$18,185,092.081,145,693View SEC Filing Icon  
5/1/2018Sell132,312$36.01$4,764,555.12View SEC Filing Icon  
8/31/2017Sell197,168$34.00$6,703,712.00580,318View SEC Filing Icon  
8/4/2017Sell96,950$34.00$3,296,300.00View SEC Filing Icon  
5/9/2016Sell275,000$33.80$9,295,000.001,446,738View SEC Filing Icon  
10/28/2013Sell338,000$30.57$10,332,660.00View SEC Filing Icon  
5/15/2013Sell69,900$29.39$2,054,361.00View SEC Filing Icon  
See Full Table

Ian C. Read Buying and Selling Activity at Pfizer

This chart shows Ian C Read's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $27.75
Low: $27.72
High: $28.12

50 Day Range

MA: $27.46
Low: $25.89
High: $28.43

2 Week Range

Now: $27.75
Low: $25.61
High: $42.22

Volume

39,620,254 shs

Average Volume

43,835,094 shs

Market Capitalization

$157.14 billion

P/E Ratio

77.08

Dividend Yield

6.09%

Beta

0.61